| Document Date: 2011-08-18 12:46:19
Open Document File Size: 50,06 KBShare Result on Facebook
City Seattle / SAN DIEGO / / Company Latterell Venture Partners / HemaQuest Pharmaceuticals Inc. / De Novo Ventures / Lilly Ventures / Forward Ventures / Aberdare Ventures / HemaQuest Pharmaceuticals / / Continent Europe / / Country Egypt / United States / Canada / Jamaica / Lebanon / / Event FDA Phase / Funding / Delayed Filing / / Facility University School / / IndustryTerm biopharmaceutical / biotechnology / treatment for this devastating disease / / MedicalCondition hemoglobin disorders / strokes / cancer / disease / chronic damage / ABOUT SICKLE CELL DISEASE Sickle cell disease / acute chest syndrome / both sickle cell disease / lymphomas / pain / lung injury / sickle cell disease / beta thalassemia / genetic blood disorder / hemoglobin diseases / Infections / / MedicalTreatment chemotherapy / / Organization Boston University School of Medicine / FDA / / Person Richard G. Ghalie / / Position Chief Medical Officer / general economic conditions / forward / Private / / Product hydroxyurea / HQK-1001 / United States / / ProvinceOrState Maryland / / Region Middle East / / Technology SCFAD technologies / biotechnology / chemotherapy / / URL www.HemaQuest.com / /
SocialTag |
Microsoft Word - HemaQuest Announces First Patient Enrolled in Phase 2 SCD Study[removed]doc